MAPT and tauopathy: The administration of ApoE-targeted ASO in an ApoE4-expressing mouse model of tauopathy, which is defined by the tau pathology common to AD, was also demonstrated to protect against tau-associated neurodegeneration and other neuropathological features of this disease, namely synaptic disruption and neuroinflammation [83].